188 related articles for article (PubMed ID: 10050867)
1. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Buller RE; Sood AK; Lallas T; Buekers T; Skilling JS
J Natl Cancer Inst; 1999 Feb; 91(4):339-46. PubMed ID: 10050867
[TBL] [Abstract][Full Text] [Related]
2. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
3. Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Boyd J; Narod SA
J Natl Cancer Inst; 1999 Sep; 91(17):1507-9. PubMed ID: 10469755
[No Abstract] [Full Text] [Related]
4. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
Buekers TE; Lallas TA; Buller RE
Gynecol Oncol; 2000 Mar; 76(3):418-22. PubMed ID: 10684722
[TBL] [Abstract][Full Text] [Related]
5. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
Schorge JO; Muto MG; Welch WR; Bandera CA; Rubin SC; Bell DA; Berkowitz RS; Mok SC
J Natl Cancer Inst; 1998 Jun; 90(11):841-5. PubMed ID: 9625172
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
7. Heterozygote BRCA1 status and skewed chromosome X inactivation.
Helbling-Leclere A; Lenoir GM; Feunteun J
Fam Cancer; 2007; 6(1):153-7. PubMed ID: 16944269
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
Wang PH; Shyong WY; Li YF; Lee HH; Tsai WY; Chao HT; Wu CY; Tsai YC; Yuan CC
Jpn J Clin Oncol; 2000 Aug; 30(8):343-8. PubMed ID: 11059339
[TBL] [Abstract][Full Text] [Related]
11. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
Kim SC; Ju W; Mahavni V; Geisler JP; Buller RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():190-4. PubMed ID: 16515589
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Hilton JL; Geisler JP; Rathe JA; Hattermann-Zogg MA; DeYoung B; Buller RE
J Natl Cancer Inst; 2002 Sep; 94(18):1396-406. PubMed ID: 12237285
[TBL] [Abstract][Full Text] [Related]
13. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
14. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
15. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
17. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the BRCA1 gene in ovarian cancers.
Takahashi H; Behbakht K; McGovern PE; Chiu HC; Couch FJ; Weber BL; Friedman LS; King MC; Furusato M; LiVolsi VA
Cancer Res; 1995 Jul; 55(14):2998-3002. PubMed ID: 7606717
[TBL] [Abstract][Full Text] [Related]
19. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
Tangir J; Muto MG; Berkowitz RS; Welch WR; Bell DA; Mok SC
Oncogene; 1996 Feb; 12(4):735-40. PubMed ID: 8632895
[TBL] [Abstract][Full Text] [Related]
20. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
